Enzyme Replacement Therapy
"Enzyme Replacement Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapeutic replacement or supplementation of defective or missing enzymes to alleviate the effects of enzyme deficiency (e.g., GLUCOSYLCERAMIDASE replacement for GAUCHER DISEASE).
Concept/Terms
Enzyme Replacement Therapy- Enzyme Replacement Therapy
- Enzyme Replacement Therapies
- Replacement Therapies, Enzyme
- Replacement Therapy, Enzyme
- Therapies, Enzyme Replacement
- Therapy, Enzyme Replacement
Below are MeSH descriptors whose meaning is more general than "Enzyme Replacement Therapy".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Replacement Therapy".
This graph shows the total number of publications written about "Enzyme Replacement Therapy" by people in Harvard Catalyst Profiles by year, and whether "Enzyme Replacement Therapy" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 3 | 2 | 5 |
| 2011 | 1 | 2 | 3 |
| 2012 | 2 | 1 | 3 |
| 2013 | 2 | 0 | 2 |
| 2014 | 0 | 5 | 5 |
| 2015 | 1 | 7 | 8 |
| 2016 | 2 | 3 | 5 |
| 2017 | 1 | 5 | 6 |
| 2018 | 3 | 1 | 4 |
| 2019 | 3 | 2 | 5 |
| 2020 | 5 | 0 | 5 |
| 2021 | 2 | 4 | 6 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
Below are the most recent publications written about "Enzyme Replacement Therapy" by people in Profiles.
-
High-Dose ERT, Rituximab, and Early HSCT in an Infant with Wolman's Disease. N Engl J Med. 2024 Feb 15; 390(7):623-629.
-
Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community. Mol Genet Metab. 2023 07; 139(3):107603.
-
Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry. Mol Genet Metab. 2023 02; 138(2):106967.
-
Long-term efficacy and safety of vestronidase alfa enzyme replacement therapy in pediatric subjects < 5 years with mucopolysaccharidosis VII. Mol Genet Metab. 2022 05; 136(1):28-37.
-
Provider Differences in Monitoring and Management of Exocrine Pancreatic Insufficiency in Chronic Pancreatitis. Pancreas. 2022 01 01; 51(1):25-27.
-
The youngest pair of siblings with Mucopolysaccharidosis type IVA to receive enzyme replacement therapy to date: A case report. Am J Med Genet A. 2021 11; 185(11):3510-3516.
-
Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort. Cardiol Young. 2022 Mar; 32(3):364-373.
-
Normal IgH Repertoire Diversity in an Infant with ADA Deficiency After Gene Therapy. J Clin Immunol. 2021 10; 41(7):1597-1606.
-
Chronic giardiasis: a rare cause of exocrine pancreatic insufficiency. BMJ Case Rep. 2021 May 07; 14(5).
-
Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome. Mol Genet Metab. 2021 06; 133(2):185-192.